CAST and beyond. Implications of the cardiac arrhythmia suppression trials. By the Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
D000813:Anilides / Q000009:adverse effects / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000401:mortality; D004311:Double-Blind Method; D016700:Encainide; D005424:Flecainide / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D016293:Moricizine; D015337:Multicenter Studies as Topic; D010640:Phenothiazines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D010640:Phenothiazines; D016293:Moricizine; D005424:Flecainide; D016700:Encainide